Lexicon Pharmaceuticals Says FDA to Hold Meeting in October to Review Zynquista for Type 1 Diabetes, CKD

08:30 AM EDT, 08/21/2024 (MT Newswires) -- Lexicon Pharmaceuticals (LXRX) said Wednesday that the US Food and Drug Administration is expected to hold an Endocrinologic and Metabolic Drugs Advisory Committee meeting on Oct. 31 to review Zynquista for use with insulin in type 1 diabetes and chronic kidney disease.

The Prescription Drug User Fee Act, or PDUFA, goal date remains Dec. 20 the company said.

Lexicon shares were up 1.3% in recent premarket activity.

Price: 1.7020, Change: +0.02, Percent Change: +1.31